Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis

Fujimura, Takashi; Yonekura, Syuji; Horiguchi, Susumu; Taniguchi, Yuriko; Saito, Akemi; Yasueda, Hiroshi; Inamine, Ayako; Nakayama, Toshinori; Takemori, Toshitada; Taniguchi, Masaru; Sakaguchi, Masahiro; Okamoto, Yoshitaka

doi:10.1016/j.clim.2010.12.022

Cited by 80 publications

(99 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in accord with the report by Fujimura et al that patients with low sIgE/tIgE ratios were more responsive to SLIT in treatment for Japanese pollinosis [7]. On the other hand, the report by Di Lorenzo et al reported a contrary result [8].…”

Section: Introductioncontrasting

confidence: 53%

Prophylactic Sublingual Immunotherapy for Japanese Cedar Pollinosis

Takeuchi¹

2016

Immunother Open Acc

View full text Add to dashboard Cite

Section: Introductioncontrasting

confidence: 53%

Prophylactic Sublingual Immunotherapy for Japanese Cedar Pollinosis

Takeuchi¹

2016

Immunother Open Acc

View full text Add to dashboard Cite

“…1,[16][17][18][19][20][21][22] Patient selection and compliance would be improved significantly if predictive biological markers were available to identify those subjects more likely to benefit from AIT.…”

Section: Discussionmentioning

confidence: 99%

“…8 Patients' eligibility to immunotherapy is currently based on the determination of IgE reactivity to a specific allergen by means of skin prick or in vitro testing. In addition, patients with either severe rhinoconjunctivitis symptoms, 16,17 high basophil responsiveness to allergens, 18 or increased allergen-specific IgE titers [19][20][21][22] before treatment appear more likely to benefit from AIT. As of today, however, no marker of AIT efficacy has been firmly established that could be used at an individual patient level to predict positive immunotherapy outcomes.…”

mentioning

confidence: 99%

Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy

Caillot

Bouley

Jain

et al. 2017

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…They found a significant improvement in QOL scores, but the effects on symptom scores were inconsistent between the two studies. Fujimura et al [14] used a treatment period of 18 months to cover 2 pollen seasons and observed the carry-over effect in the 3rd pollen season without treatment. Treatment for 18 months had efficacy in the 2nd pollen season and in the 3rd season after treatment was terminated, but failed to show a significant effect in the 1st season [14].…”

Section: Introductionmentioning

confidence: 99%

“…Clinical studies of the efficacy and safety of SLIT for JC pollinosis have been conducted in small populations of patients [12,13,14]. In these studies, standardized JC pollen extract for SCIT was applied in the sublingual cavity and spat out after 2 min.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Sublingual Immunotherapy for Two Seasons in Patients with Japanese Cedar Pollinosis

Okamoto

Okubo

Yonekura

et al. 2015

Int Arch Allergy Immunol

Self Cite

109

View full text Add to dashboard Cite

Background: Japanese cedar (JC) pollinosis is the most common seasonal allergic rhinitis in Japan. Standardized JC pollen extract is available for subcutaneous immunotherapy, but this treatment is limited by potentially serious side effects. The aim of this double-blind, randomized comparative study was to evaluate the efficacy and safety of standardized JC pollen extract in a new oral formulation (CEDARTOLEN®, Torii Pharmaceutical Co., Ltd., Tokyo, Japan) for sublingual immunotherapy (SLIT) for JC pollinosis. Methods: A total of 531 subjects with JC pollinosis were randomized into 2 groups at a ratio of 1:1 to receive daily sublingual administration of standardized JC pollen extract with a maintenance dose of 2,000 Japanese allergy units (JAU) or placebo for 2 consecutive pollen seasons. The efficacy was evaluated using the total nasal symptom and medication score (TNSMS) as the primary end point. Secondary end points included the total ocular symptom and medication score (TOSMS) and scores for individual symptoms and medication. Results: The TNSMS was significantly lower (p < 0.0001) in the SLIT group than in the placebo group in the peak symptom period by 18 and 30% in the first and second seasons, respectively. All secondary end points were also significantly lower in the SLIT group in both seasons. No systemic anaphylaxis occurred. Conclusions: SLIT with daily administration of standardized JC pollen extract was effective for improving nasal and ocular symptoms of JC pollinosis and reducing the use of relief medication. The JC pollen extract was well tolerated with only local adverse events.

show abstract

Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis

Cited by 80 publications

References 19 publications

Prophylactic Sublingual Immunotherapy for Japanese Cedar Pollinosis

Prophylactic Sublingual Immunotherapy for Japanese Cedar Pollinosis

Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy

Efficacy and Safety of Sublingual Immunotherapy for Two Seasons in Patients with Japanese Cedar Pollinosis

Contact Info

Product

Resources

About